225 related articles for article (PubMed ID: 15497163)
1. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.
Neff GW; O'brien CB; Nery J; Shire N; Montalbano M; Ruiz P; Nery C; Safdar K; De Medina M; Tzakis AG; Schiff ER; Madariaga J
Liver Transpl; 2004 Nov; 10(11):1372-8. PubMed ID: 15497163
[TBL] [Abstract][Full Text] [Related]
2. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
[TBL] [Abstract][Full Text] [Related]
4. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
[TBL] [Abstract][Full Text] [Related]
6. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
7. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
[TBL] [Abstract][Full Text] [Related]
11. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
Bárcena R; Del Campo S; Moraleda G; Casanovas T; Prieto M; Buti M; Moreno JM; Cuervas V; Fraga E; De la Mata M; Otero A; Delgado M; Loinaz C; Barrios C; Dieguez ML; Mas A; Sousa JM; Herrero JI; Muñoz R; Avilés JF; Gonzalez A; Rueda M
Transplant Proc; 2005 Nov; 37(9):3960-2. PubMed ID: 16386596
[TBL] [Abstract][Full Text] [Related]
12. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.
Stravitz RT; Shiffman ML; Kimmel M; Puri P; Luketic VA; Sterling RK; Sanyal AJ; Cotterell AH; Posner MP; Fisher RA
Liver Int; 2012 Aug; 32(7):1138-45. PubMed ID: 22348467
[TBL] [Abstract][Full Text] [Related]
13. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
Ołdakowska-Jedynak U; Paczek L; Foroncewicz B; Mucha K; Nyckowski P; Zieniewicz K; Ziarkiewicz-Wróblewska B; Ziółkowski J; Pilecki T; Patkowski W; Górnicka B; Paczkowska A; Krawczyk M
Ann Transplant; 2007; 12(3):28-32. PubMed ID: 18290567
[TBL] [Abstract][Full Text] [Related]
14. Living donor liver transplantation for hepatitis B associated liver diseases: a 10-year experience in a single center.
Ikegami T; Soejima Y; Ohta R; Taketomi A; Yoshizumi T; Harada N; Kayashima H; Maehara Y
Hepatogastroenterology; 2008; 55(85):1445-9. PubMed ID: 18795708
[TBL] [Abstract][Full Text] [Related]
15. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
[TBL] [Abstract][Full Text] [Related]
16. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant.
Wai CT; Prabhakaran K; Wee A; Lee YM; Dan YY; Sutedja DS; Mak K; Isaac J; Lee KH; Lee HL; Da Costa M; Lim SG
Transplant Proc; 2004 Oct; 36(8):2313-4. PubMed ID: 15561234
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
18. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
19. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
[TBL] [Abstract][Full Text] [Related]
20. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection.
Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V
Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]